• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

使用 MHC Ⅰ类和Ⅱ类四聚体评估 SARS-CoV-2 特异性 CD4(+)和 CD8 (+) T 细胞应答。

Assessment of SARS-CoV-2 specific CD4(+) and CD8 (+) T cell responses using MHC class I and II tetramers.

机构信息

MBL International, 15A Constitution Way, Woburn, MA 01801, United States.

JSR Life Sciences, 1280 N Mathilda Ave, Sunnyvale, CA 94089, United States.

出版信息

Vaccine. 2021 Apr 8;39(15):2110-2116. doi: 10.1016/j.vaccine.2021.03.008. Epub 2021 Mar 5.

DOI:10.1016/j.vaccine.2021.03.008
PMID:33744048
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7934687/
Abstract

The success of SARS-CoV-2 (CoV-2) vaccines is measured by their ability to mount immune memory responses that are long-lasting. To achieve this goal, it is important to identify surrogates of immune protection, namely, CoV-2 MHC Class I and II immunodominant pieces/epitopes and methodologies to measure them. Here, we present results of flow cytometry-based MHC Class I and II QuickSwitch platforms for assessing SARS-CoV-2 peptide binding affinities to various human alleles as well as the H-2 Kb mouse allele. Multiple SARS-CoV-2 potential MHC binders were screened and validated by QuickSwitch testing. The screen included 31 MHC Class I and 19 MHC Class II peptides predicted to be good binders by the IEDB web resource provided by NIAID. While several predicted peptides with acceptable theoretical Kd showed poor MHC occupancies, fourteen MHC class II and three MHC class I peptides showed promiscuity in that they bind to multiple MHC molecule types. In addition to providing important data towards the study of the SARS-CoV-2 virus and its presented antigenic epitopes, the peptides identified in this study can be used in the QuickSwitch platform to generate MHC tetramers. With those tetramers, scientists can assess CD4 + and CD8 + immune responses to these different MHC/peptide complexes.

摘要

SARS-CoV-2(CoV-2)疫苗的成功与否取决于其能否产生持久的免疫记忆反应。为了实现这一目标,识别免疫保护的替代物非常重要,即 CoV-2 MHC Ⅰ类和Ⅱ类免疫显性片段/表位,以及测量它们的方法。在这里,我们展示了基于流式细胞术的 MHC Ⅰ类和Ⅱ类 QuickSwitch 平台的结果,用于评估 SARS-CoV-2 肽与各种人类等位基因以及 H-2 Kb 小鼠等位基因的结合亲和力。通过 QuickSwitch 测试筛选和验证了多个 SARS-CoV-2 潜在的 MHC 结合物。该筛选包括 31 种 MHC Ⅰ类和 19 种 MHC Ⅱ类肽,这些肽被 NIAID 提供的 IEDB 网络资源预测为良好的结合物。虽然几个具有可接受理论 Kd 的预测肽显示出较差的 MHC 占有率,但 14 种 MHC Ⅱ类和 3 种 MHC Ⅰ类肽表现出混杂性,即它们与多种 MHC 分子类型结合。除了为 SARS-CoV-2 病毒及其呈现的抗原表位研究提供重要数据外,本研究中鉴定的肽可用于 QuickSwitch 平台生成 MHC 四聚体。有了这些四聚体,科学家们可以评估针对这些不同 MHC/肽复合物的 CD4+和 CD8+免疫反应。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/44b7/7934687/3345d86825a9/gr4_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/44b7/7934687/3a808776c965/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/44b7/7934687/1cbc1e4600e8/gr2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/44b7/7934687/c87919526b42/gr3_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/44b7/7934687/3345d86825a9/gr4_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/44b7/7934687/3a808776c965/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/44b7/7934687/1cbc1e4600e8/gr2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/44b7/7934687/c87919526b42/gr3_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/44b7/7934687/3345d86825a9/gr4_lrg.jpg

相似文献

1
Assessment of SARS-CoV-2 specific CD4(+) and CD8 (+) T cell responses using MHC class I and II tetramers.使用 MHC Ⅰ类和Ⅱ类四聚体评估 SARS-CoV-2 特异性 CD4(+)和 CD8 (+) T 细胞应答。
Vaccine. 2021 Apr 8;39(15):2110-2116. doi: 10.1016/j.vaccine.2021.03.008. Epub 2021 Mar 5.
2
A Systematic, Unbiased Mapping of CD8 and CD4 T Cell Epitopes in Yellow Fever Vaccinees.黄热病疫苗接种者中 CD8 和 CD4 T 细胞表位的系统、无偏映射。
Front Immunol. 2020 Aug 31;11:1836. doi: 10.3389/fimmu.2020.01836. eCollection 2020.
3
T cell responses to bluetongue virus are directed against multiple and identical CD4+ and CD8+ T cell epitopes from the VP7 core protein in mouse and sheep.T 细胞对蓝舌病病毒的反应针对的是来自 VP7 核心蛋白的多个相同的 CD4+ 和 CD8+ T 细胞表位,在小鼠和绵羊中均有体现。
Vaccine. 2011 Sep 16;29(40):6848-57. doi: 10.1016/j.vaccine.2011.07.061. Epub 2011 Jul 30.
4
Immuno-informatics design of a multimeric epitope peptide based vaccine targeting SARS-CoV-2 spike glycoprotein.基于 SARS-CoV-2 刺突糖蛋白的多聚表位肽疫苗的免疫信息学设计。
PLoS One. 2021 Mar 17;16(3):e0248061. doi: 10.1371/journal.pone.0248061. eCollection 2021.
5
SARS-CoV-2 specific memory T cell epitopes identified in COVID-19-recovered subjects.在 COVID-19 康复者中鉴定出的 SARS-CoV-2 特异性记忆 T 细胞表位。
Virus Res. 2021 Oct 15;304:198508. doi: 10.1016/j.virusres.2021.198508. Epub 2021 Jul 27.
6
Acute-Phase CD4 T Cell Responses Targeting Invariant Viral Regions Are Associated with Control of Live Attenuated Simian Immunodeficiency Virus.针对不变病毒区域的急性相 CD4 T 细胞反应与活减毒猴免疫缺陷病毒的控制有关。
J Virol. 2018 Oct 12;92(21). doi: 10.1128/JVI.00830-18. Print 2018 Nov 1.
7
Immunization with a peptide containing MHC class I and II epitopes derived from the tumor antigen SIM2 induces an effective CD4 and CD8 T-cell response.用包含源自肿瘤抗原SIM2的MHC I类和II类表位的肽进行免疫可诱导有效的CD4和CD8 T细胞应答。
PLoS One. 2014 Apr 1;9(4):e93231. doi: 10.1371/journal.pone.0093231. eCollection 2014.
8
SARS-CoV-2 genome-wide T cell epitope mapping reveals immunodominance and substantial CD8 T cell activation in COVID-19 patients.SARS-CoV-2 全基因组 T 细胞表位图谱分析揭示了 COVID-19 患者中的免疫优势和大量 CD8+T 细胞激活。
Sci Immunol. 2021 Apr 14;6(58). doi: 10.1126/sciimmunol.abf7550.
9
Identification of MHC class II restricted T-cell-mediated reactivity against MHC class I binding Mycobacterium tuberculosis peptides.鉴定 MHC Ⅱ类限制的 T 细胞对 MHC Ⅰ类结合结核分枝杆菌肽的反应性。
Immunology. 2011 Apr;132(4):482-91. doi: 10.1111/j.1365-2567.2010.03383.x. Epub 2011 Feb 7.
10
Mapping the immunopeptidome of seven SARS-CoV-2 antigens across common HLA haplotypes.绘制七种 SARS-CoV-2 抗原在常见 HLA 单倍型上的免疫肽组图谱。
Nat Commun. 2024 Aug 30;15(1):7547. doi: 10.1038/s41467-024-51959-6.

引用本文的文献

1
Exploring Immune Responses to SARS-CoV-2: Insights from Sinopharm (BBIBP-CorV)-Vaccinated Individuals in a Group of Venezuelan Admixed Volunteers.探索对SARS-CoV-2的免疫反应:来自一组委内瑞拉混血志愿者中接种国药集团(BBIBP-CorV)疫苗个体的见解。
Biomedicines. 2025 Jun 25;13(7):1550. doi: 10.3390/biomedicines13071550.
2
Humanized Major Histocompatibility Complex Transgenic Mouse Model Can Play a Potent Role in SARS-CoV-2 Human Leukocyte Antigen-Restricted T Cell Epitope Screening.人源化主要组织相容性复合体转基因小鼠模型在严重急性呼吸综合征冠状病毒2人白细胞抗原限制性T细胞表位筛选中可发挥重要作用。
Vaccines (Basel). 2025 Apr 15;13(4):416. doi: 10.3390/vaccines13040416.
3

本文引用的文献

1
Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans.未暴露于 SARS-CoV-2 人群中的选择性和交叉反应性 T 细胞表位。
Science. 2020 Oct 2;370(6512):89-94. doi: 10.1126/science.abd3871. Epub 2020 Aug 4.
2
Phenotype and kinetics of SARS-CoV-2-specific T cells in COVID-19 patients with acute respiratory distress syndrome.急性呼吸窘迫综合征的 COVID-19 患者中 SARS-CoV-2 特异性 T 细胞的表型和动力学。
Sci Immunol. 2020 Jun 26;5(48). doi: 10.1126/sciimmunol.abd2071.
3
Systemically comparing host immunity between survived and deceased COVID-19 patients.
LNP-RNA-mediated antigen presentation leverages SARS-CoV-2-specific immunity for cancer treatment.
脂质纳米颗粒-核糖核酸介导的抗原呈递利用针对严重急性呼吸综合征冠状病毒2的特异性免疫来进行癌症治疗。
Nat Commun. 2025 Mar 4;16(1):2198. doi: 10.1038/s41467-025-57149-2.
4
Broad protection and respiratory immunity of dual mRNA vaccination against SARS-CoV-2 variants.针对新冠病毒变异株的双信使核糖核酸疫苗接种具有广泛保护作用和呼吸道免疫力。
NPJ Vaccines. 2024 Sep 4;9(1):160. doi: 10.1038/s41541-024-00957-2.
5
mRNA-LNP vaccine-induced CD8 T cells protect mice from lethal SARS-CoV-2 infection in the absence of specific antibodies.mRNA-LNP 疫苗诱导的 CD8 T 细胞在没有特异性抗体的情况下保护小鼠免受致死性 SARS-CoV-2 感染。
Mol Ther. 2024 Jun 5;32(6):1790-1804. doi: 10.1016/j.ymthe.2024.04.019. Epub 2024 Apr 11.
6
A quest for universal anti-SARS-CoV-2 T cell assay: systematic review, meta-analysis, and experimental validation.寻求通用的抗SARS-CoV-2 T细胞检测方法:系统评价、荟萃分析和实验验证。
NPJ Vaccines. 2024 Jan 2;9(1):3. doi: 10.1038/s41541-023-00794-9.
7
Multiantigen pan-sarbecovirus DNA vaccines generate protective T cell immune responses.多抗原泛沙贝科病毒 DNA 疫苗可产生保护性 T 细胞免疫应答。
JCI Insight. 2023 Nov 8;8(21):e172488. doi: 10.1172/jci.insight.172488.
8
Cell type-specific delivery by modular envelope design.模块化包膜设计的细胞类型特异性递送。
Nat Commun. 2023 Aug 23;14(1):5141. doi: 10.1038/s41467-023-40788-8.
9
Structural definition of HLA class II-presented SARS-CoV-2 epitopes reveals a mechanism to escape pre-existing CD4 T cell immunity.结构定义 HLA II 类呈递的 SARS-CoV-2 表位揭示了逃避预先存在的 CD4 T 细胞免疫的机制。
Cell Rep. 2023 Aug 29;42(8):112827. doi: 10.1016/j.celrep.2023.112827. Epub 2023 Jul 19.
10
An mRNA-based T-cell-inducing antigen strengthens COVID-19 vaccine against SARS-CoV-2 variants.一种基于 mRNA 的 T 细胞诱导抗原增强了 COVID-19 疫苗对 SARS-CoV-2 变体的效力。
Nat Commun. 2023 May 23;14(1):2962. doi: 10.1038/s41467-023-38751-8.
系统比较新冠病毒肺炎幸存者与死亡患者之间的宿主免疫力。
Cell Mol Immunol. 2020 Aug;17(8):875-877. doi: 10.1038/s41423-020-0483-y. Epub 2020 Jun 15.
4
Passive antibody therapy in COVID-19.COVID-19 的被动抗体治疗。
Nat Rev Immunol. 2020 Jul;20(7):401-403. doi: 10.1038/s41577-020-0365-7.
5
Long-term maintenance of lung resident memory T cells is mediated by persistent antigen.持续性抗原介导肺驻留记忆 T 细胞的长期维持。
Mucosal Immunol. 2021 Jan;14(1):92-99. doi: 10.1038/s41385-020-0309-3. Epub 2020 Jun 9.
6
Immunogenicity of a DNA vaccine candidate for COVID-19.针对 COVID-19 的 DNA 疫苗候选物的免疫原性。
Nat Commun. 2020 May 20;11(1):2601. doi: 10.1038/s41467-020-16505-0.
7
Human Leukocyte Antigen Susceptibility Map for Severe Acute Respiratory Syndrome Coronavirus 2.人类白细胞抗原易感性图谱与严重急性呼吸综合征冠状病毒 2。
J Virol. 2020 Jun 16;94(13). doi: 10.1128/JVI.00510-20.
8
In Silico-Guided Sequence Modification of Epitopes in Cancer Vaccine Development.基于计算机的导向的癌症疫苗开发中抗原表位的序列修饰。
Methods Mol Biol. 2020;2131:213-228. doi: 10.1007/978-1-0716-0389-5_10.
9
Machine-Learning Prediction of Tumor Antigen Immunogenicity in the Selection of Therapeutic Epitopes.基于机器学习的肿瘤抗原免疫原性预测在治疗性表位选择中的应用。
Cancer Immunol Res. 2019 Oct;7(10):1591-1604. doi: 10.1158/2326-6066.CIR-19-0155. Epub 2019 Sep 12.
10
In Vitro Studies of MHC Class I Peptide Loading and Exchange.MHC I类肽装载与交换的体外研究
Methods Mol Biol. 2019;1988:71-81. doi: 10.1007/978-1-4939-9450-2_6.